Researchers identify key compounds to resolve abnormal vascular growth in AMD

August 21, 2017, Massachusetts Eye and Ear Infirmary
Choroidal neovascular (CNV) lesion with associated blood vessels (red) and immune cells (Green). Credit: Massachusetts Eye and Ear

A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers. The report, published online in the Proceedings of the National Academy of Sciences, suggests that it may be possible to prevent the vision loss resulting from disease-causing angiogenesis and inflammation observed in wet AMD by increasing the expression of specific bioactive lipid metabolites in the retina. The research demonstrates that these bioactive lipids have the ability to regulate inflammatory immune cells in the retina, key regulators of the angiogenic process in this disease. Given this, these molecules show promising therapeutic potential not only for AMD, but also for other major conditions that involve angiogenesis and inflammation, such as cardiovascular disease and cancer.

"Given the high prevalence and progressive nature of neovascular eye disease, the ability to stabilize bioactive lipids that mitigate or halt disease is of great and increasingly therapeutic significance," said corresponding author Kip Connor, Ph.D., a vision scientist at Mass. Eye and Ear and Assistant Professor of Ophthalmology at Harvard Medical School. "It is our hope that emerging technologies and future studies will expand on our work, and ultimately lead to safe, targeted, and cost-effective therapies that markedly improve visual outcomes and quality of life for patients suffering from these debilitating eye diseases."

The most common cause of elderly blindness in the developed world, AMD is a chronic, progressive disease affecting as many as 11 million Americans, and that number is expected to double by 2020. Globally, approximately 196 million are projected to develop AMD by 2020. The risk of developing AMD increases from 2 percent for those ages 50-59, to nearly 30 percent for those over the age of 75.

Disease-causing angiogenesis is a feature of advanced AMD in which blood vessels in the retina (the structure in the back of the eye that senses and perceives light) begin to grow new, abnormal blood vessels on the surface of the retina. These new vessels are immature, and can leak, rupture, or cause retinal detachment. Such cases, termed neovascular or "wet" AMD, account for 10 to 15 percent of AMD cases, develop abruptly, and rapidly lead to substantial vision loss.

Previous research has largely ignored the role of immune cells in advanced AMD, but the PNAS report suggests that they are likely are a major contributor in the pathologic process. The researchers identified key compounds of the cytochrome P450 (CYP) pathway, a major family of enzymes, and showed that the compound can influence angiogenesis, changing how are recruited to areas of disease and injury. Specifically, they isolated and characterized two key mediators of disease resolution generated from the CYP pathway: 17,18-epoxyeicosatetraenoic acid (EEQ) and 19,20-epoxydocosapentaenoic acid (EDP). These compounds successfully protected animal models of AMD from developing .

The findings have significant therapeutic implications, not only for AMD, but also for other inflammatory disorders.

"Our research shows how rapidly fundamental knowledge of physiology and regulatory biology can be translated to practical solutions for a major type of blindness," said co-author Bruce Hammock, Ph.D., a Distinguished Professor who holds a joint appointment with the UC Davis Department of Entomology and Nematology and the UC Davis Comprehensive Cancer Center. Dr. Hammock expressed hope that the team Dr. Connor has organized will "find a solution to a devastating human health program."

"Although we do not fully understand how and why AMD develops, identifying additional mechanisms that regulate abnormal blood vessel growth in the eye beyond what we currently know could open up a range of possibilities for new research and treatments for AMD," Dr. Connor said.

Explore further: Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

More information: Eiichi Hasegawa el al., "Cytochrome P450 monooxygenase lipid metabolites are significant second messengers in the resolution of choroidal neovascularization," PNAS (2017). www.pnas.org/cgi/doi/10.1073/pnas.1620898114

Related Stories

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Researchers identify new target for abnormal blood vessel growth in the eyes

April 11, 2017
A team led by Massachusetts Eye and Ear researchers has identified a novel therapeutic target for retinal neovascularization, or abnormal blood vessel growth in the retina, a hallmark of advanced diabetic eye disease (proliferative ...

Omega-3 inhibits blood vessel growth in age-related macular degeneration

June 16, 2014
Age-related macular degeneration (AMD), which is characterized by choroidal neovascularization (CNV), or blood vessel growth, is the primary cause of blindness in elderly individuals of industrialized countries. The prevalence ...

Researchers define a spontaneous retinal neovascular mouse model

September 4, 2014
Neovascular age-related macular degeneration (AMD), which involves formation of abnormal blood vessels in the retina, is a leading cause of vision loss. A subgroup of neovascular AMD, known as retinal angiomatous proliferation ...

Blocking angiogenesis to stop cancer growth and target other diseases

April 25, 2017
Newly published UC Davis research characterizing specific mechanisms involved in blocking angiogenesis, or the formation new blood vessels, has the potential to block cancer growth and target other diseases, researchers said ...

New clues found to vision loss in macular degeneration?

August 11, 2015
Scientists have identified a pathway that leads to the formation of atypical blood vessels that can cause blindness in people with age-related macular degeneration.

Recommended for you

Satellite imaging techniques may help reduce preventable vision loss

May 11, 2018
By adapting pattern recognition techniques used to assess satellite images, scientists have devised a novel way to diagnose blinding eye diseases, such as age-related macular degeneration.

Ophthalmologists link immunotherapy with a serious eye condition

May 7, 2018
New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

Burnout, depression can affect ophthalmology residents, study finds

May 4, 2018
A new study led by Brown University researchers finds that ophthalmology residents across the U.S. face a substantial burden of burnout and depression, which may affect not only the residents themselves but also the quality ...

AI better than most human experts at detecting cause of preemie blindness

May 3, 2018
An algorithm that uses artificial intelligence can automatically and more accurately diagnose a potentially devastating cause of childhood blindness than most expert physicians, a paper published in JAMA Ophthalmology suggests.

New diagnostic technique picks up the S in vision

May 1, 2018
A new technique that could help improve diagnosis of vision disorders has been successfully tested at the University of Bradford, UK.

A bit of dark chocolate might sweeten your vision

April 26, 2018
It may not replace prescription glasses, but a few bites of dark chocolate might offer a slight and temporary bump up in vision quality, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.